Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 220 clinical trials
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma

The purpose of this study is to evaluate the tolerance of one year of ketogenic diet associated with vitamin supplementation in patients treated for a metastatic renal cell carcinoma.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.

  • 0 views
  • 14 May, 2022
  • 5 locations
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG

This phase I/II trials evaluates the feasibility, safety and efficacy of an individualized cancer vaccine, based on autologous, tumor-lysate loaded dendritic cells in children and adolescents with relapsed high-grade gliomas. In addition, regulatory T cells are depleted by a short cycle of metronomic cyclophosphamide upfront of the vaccine in order …

  • 0 views
  • 11 May, 2022
  • 1 location
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

With the introduction of checkpoint inhibitors substantial improvements have been made in the treatment of malignant melanoma (MM). Despite this still a a subset of patients, approximately 50 %, experience no response to therapy. One of the strategies to overcome these obstacles have been ACT with tumour infiltrating lymphocytes (TILs). …

direct bilirubin
cancer
metastatic melanoma
cyclophosphamide
neutrophil count
  • 0 views
  • 25 Sep, 2021
  • 1 location
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically. In the last 2 years, immune check points inhibitors (mainly Programmed Death (PD)-1 inhibitors) were approved for metastatic/recurrent HNC. The favorable toxicity profile and …

  • 55 views
  • 15 Feb, 2022
  • 1 location
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in metastatic

vaccination
cancer
platelet count
pembrolizumab
direct bilirubin
  • 0 views
  • 26 Apr, 2022
  • 35 locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune

choriocarcinoma
immunosuppressive agents
immunosuppressive
germ cell tumor
ovarian epithelial carcinoma
  • 6632 views
  • 29 Jun, 2022
  • 759 locations
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab

ipilimumab
metastatic melanoma
BRAF
ct scan
measurable disease
  • 11 views
  • 16 Feb, 2022
  • 39 locations
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.

platelet count
total bilirubin
chemotherapy regimen
pemetrexed
malignant mesothelioma
  • 62 views
  • 02 Nov, 2021
  • 7 locations
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

measurable disease
solid tumor
nivolumab
  • 61 views
  • 28 May, 2022
  • 28 locations